Allogene cema-cel posts 58.3% MRD clearance in ALPHA3 first-line LBCL consolidation study

• Allogene Therapeutics received FDA RMAT designation for cema-cel as first-line consolidation therapy in MRD-positive large B-cell lymphoma.
• The designations were based on interim results already presented from a futility analysis in the ongoing ALPHA3 pivotal trial.
• The analysis showed cema-cel improved disease-detection clearance versus observation, supporting its positioning as an earlier-line, off-the-shelf CAR-T option.
• FDA also granted Fast Track designation for the ALPHA3 program, setting up closer agency engagement and potential expedited development and review.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allogene Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607290830PRIMZONEFULLFEED9799886) on July 29, 2026, and is solely responsible for the information contained therein.